Table 3

Patient and tumor characteristics and response to chemotherapy of patients with recurrent disease

No. of patientsUp-front chemotherapyNo. of patientsChemotherapy after tamoxifen
ResponseUnivariateResponseUnivariate
(%)POR95% CI(%)POR95% CI
All patients414611345
Menopausal status
Premenopausal2361129481
Postmenopausal18280.030.250.07–0.9384440.690.840.36–1.97
Age (yr)
<401050110501
40–5518561.250.27–5.8939490.950.24–3.81
55–657430.750.11–5.2434470.890.22–3.64
>656170.380.200.02–2.3930370.750.580.14–2.46
Dominant site of relapse
Soft tissue10401 4a501
Bone10602.250.38–13.4746521.090.14–8.42
Visceral21430.601.130.24–5.2163400.420.660.09–4.98
Disease-free interval (mo)
<122055139441
>1221380.280.500.14–1.7574460.811.100.50–2.40
Prior adjuvant therapy
No2948196451
Yes12420.700.770.20–2.9817470.861.100.39–3.08
ER levels (fmol/mg protein)
<102646121431
10–7511551.400.34–5.7631451.100.36–3.35
>754250.590.390.04–4.2560470.951.170.43–3.18
PgR levels (fmol/mg protein)
<102948129411
10–757430.800.15–4.2540431.050.40–2.76
>755400.920.710.10–4.9342500.711.420.55–3.68
TP53 gene status
Wild type1663173421
Mutated25360.100.340.09–1.2440500.441.350.62–2.94
  • a Dominant site of relapse at start of chemotherapy after tamoxifen treatment. Significant data are shown in bold.